Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN)

被引:13
作者
Jensen, Alexandra D. [1 ]
Krauss, Juergen [2 ]
Weichert, Wilko [3 ]
Bergmann, Zazie P. [4 ]
Freier, Kolja [5 ]
Debus, Juergen [1 ]
Muenter, Marc W. [1 ]
机构
[1] INF 400, Dept Radiat Oncol, D-69120 Heidelberg, Germany
[2] Natl Ctr Tumour Dis NCT, D-69120 Heidelberg, Germany
[3] Inst Pathol, D-69120 Heidelberg, Germany
[4] Dept Head & Neck Surg, D-69120 Heidelberg, Germany
[5] Dept Oromaxillofacial Surg, D-69120 Heidelberg, Germany
关键词
INTENSITY-MODULATED RADIOTHERAPY; SALIVARY-GLAND FUNCTION; QUANTITATIVE PERTECHNETATE SCINTIGRAPHY; STAGE NASOPHARYNGEAL CARCINOMA; QUALITY-OF-LIFE; RADIATION-THERAPY; DEFINITIVE RADIOTHERAPY; SWALLOWING DYSFUNCTION; CANCER; CHEMOTHERAPY;
D O I
10.1186/1748-717X-6-122
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To report our experience on disease control and functional outcome using three modern combined-modality approaches for definitive radiochemotherapy of locally advanced SCCHN with modern radiotherapy techniques: radiochemotherapy (RChT), radioimmunotherapy (RIT) with cetuximab, or induction chemotherapy with docetaxel, cisplatin, and 5-FU (TPF) combined with either RChT or RIT. Methods: Toxicity and outcome was retrospectively analysed in patients receiving definitive RChT, RIT, or induction chemotherapy followed by RChT or RIT between 2006 and 2009. Outcome was estimated using Kaplan-Meier analyses, toxicity was analysed according to CTCAE v 3.0. Results: Thirty-eight patients were treated with RChT, 38 patients with RIT, 16 patients received TPF followed by either RChT or RIT. Radiotherapy was mostly applied as IMRT (68%). Long-term toxicity was low, only one case of grad III dysphagia requiring oesophageal dilatation, no case of either xerostomia >= grade II or cervical plexopathy were observed. Median overall survival (OS) was 25.7 months (RChT) and 27.7 months (RIT), median locoregional progression-free survival (PFS) was not reached yet. Subgroup analysis showed no significant differences between TPF, RChT, and RIT despite higher age and co-morbidities in the RIT group. Results suggested improved OS, distant and overall PFS for the TPF regimen. Conclusion: Late radiation effects in our cohort are rare. No significant differences in outcome between RChT and RIT were observed. Adding TPF suggests improved progression-free and overall survival, impact of TPF on locoregional PFS was marginal, therefore radiotherapeutic options for intensification of local treatment should be explored.
引用
收藏
页数:9
相关论文
共 39 条
[1]   Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer [J].
Adelstein, DJ ;
Li, Y ;
Adams, GL ;
Wagner, H ;
Kish, JA ;
Ensley, JF ;
Schuller, DE ;
Forastiere, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :92-98
[2]   Prognostic factors in oropharyngeal cancer - analysis of 627 cases receiving definitive radiotherapy [J].
Agarwal, Jai Prakash ;
Mallick, Indranil ;
Bhutani, Ritu ;
Ghosh-Laskar, Sarbani ;
Gupta, Tejpal ;
Budrukkar, Ashwini ;
Murthy, Vedang ;
Sengar, Manju ;
Dinshaw, Ketayun A. .
ACTA ONCOLOGICA, 2009, 48 (07) :1026-1033
[3]   Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation therapy oncology group phase II trial 99-14 [J].
Ang, KK ;
Harris, J ;
Garden, AS ;
Trotti, A ;
Jones, CU ;
Carrascosa, L ;
Cheng, JD ;
Spencer, SS ;
Forastiere, A ;
Weber, RS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :3008-3015
[4]   Cetuximab combined with radiotherapy: An alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? [J].
Bernier, J. ;
Schneider, D. .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (01) :35-45
[5]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[6]   Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J].
Bonner, James A. ;
Harari, Paul M. ;
Giralt, Jordi ;
Cohen, Roger B. ;
Jones, Christopher U. ;
Sur, Ranjan K. ;
Raben, David ;
Baselga, Jose ;
Spencer, Sharon A. ;
Zhu, Junming ;
Youssoufian, Hagop ;
Rowinsky, Eric K. ;
Ang, K. Kian .
LANCET ONCOLOGY, 2010, 11 (01) :21-28
[7]   Locoregionally advanced head and neck cancer treated with primary radiotherapy: A comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment [J].
Caudell, Jimmy J. ;
Sawrie, Stephen M. ;
Spencer, Sharon A. ;
Desmond, Renee A. ;
Carroll, William R. ;
Peters, Glenn E. ;
Nabell, Lisle M. ;
Meredith, Ruby F. ;
Bonner, James A. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (03) :676-681
[8]  
Clavel S, 2009, J CLIN ONCOL, V27
[9]  
Cooper JS, 1996, CANCER, V77, P1905, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1905::AID-CNCR22>3.0.CO
[10]  
2-2